C4 Therapeutics Inc represents strong values and a clear corporate philosophy. As a leading biotechnology company, C4 Therapeutics is dedicated to developing targeted protein degradation (TPD) therapies to treat a wide range of diseases. The company believes in the transformative potential of its TPD platform, which selectively and efficiently eliminates disease-causing proteins. C4 Therapeutics values innovation, scientific excellence, and a patient-centric approach in its pursuit of novel therapies. With a commitment to improving patient outcomes, C4 Therapeutics strives to deliver innovative solutions that address unmet medical needs and bring new hope to patients worldwide.

C4 Therapeutics Inc is primarily present in the United States.

C4 Therapeutics Inc has achieved several significant milestones. In the past few years, the company has successfully secured multiple partnerships and collaborations with renowned pharmaceutical companies, facilitating the development of innovative therapeutics. Additionally, C4 Therapeutics Inc has demonstrated promising results in preclinical studies, showcasing the therapeutic potential of their targeted protein degradation platform. The company has also successfully raised substantial funding through public offerings, enabling them to advance their research and development efforts. These achievements highlight C4 Therapeutics Inc's dedication to revolutionizing drug discovery and development through their cutting-edge technologies and strategic collaborations.

C4 Therapeutics Inc is a biopharmaceutical company focused on developing novel therapies for the treatment of cancer. Established in 2015, the company combines expertise in targeted protein degradation with innovative small molecule drug discovery to address unmet medical needs. C4T's proprietary Degronimid platform enables the selective elimination of disease-causing proteins, providing a potential breakthrough approach in oncology and other diseases. Through strategic partnerships and collaborations, C4 Therapeutics is advancing its pipeline of drug candidates towards clinical development. With a strong commitment to scientific excellence, C4 Therapeutics aims to revolutionize cancer treatment options and improve patient outcomes.

The main competitors of C4 Therapeutics Inc in the market are other companies operating in the field of targeted protein degradation, such as Arvinas Inc, Kymera Therapeutics, Nurix Therapeutics, and PROLynx LLC. These companies are also focused on developing novel therapies that harness the body's natural protein disposal system to selectively eliminate disease-causing proteins. However, C4 Therapeutics Inc aims to differentiate itself through its unique Targeted Protein Degradation (TPD) platform and proprietary small molecule drugs, making it a key player in this competitive market.

C4 Therapeutics Inc is primarily active in the biotechnology industry.

The business model of C4 Therapeutics Inc revolves around targeted protein degradation. By leveraging their proprietary technology, they aim to develop small molecule drugs that can selectively eliminate disease-causing proteins. Their approach offers a potential breakthrough in addressing a wide range of diseases including cancer, neurodegenerative disorders, and autoimmune conditions. C4 Therapeutics focuses on developing drug candidates known as DegronimidTM molecules, which could provide a more precise and efficient way of degrading proteins compared to traditional methods. Through their innovative research and development efforts, C4 Therapeutics Inc aims to bring transformative therapies to patients in need.

Rasio P/E C4 Therapeutics adalah -1,61.

Rasio KUV dari C4 Therapeutics adalah 6,95.

Skor Kualitas AlleAktien untuk C4 Therapeutics adalah 2/10.

Omset diharapkan C4 Therapeutics adalah 25,59 Juta. USD.

Laba diharapkan C4 Therapeutics adalah -110,21 Juta. USD.

C4 Therapeutics Inc. is a biopharmaceutical company that focuses on the development of Targeted Protein Degradation (TPD) therapeutics. The company was founded in 2015 in Massachusetts, USA, and has since been focused on developing drugs that target the elimination of abnormal disease-causing proteins. C4 Therapeutics' business model is based on the combination of artificial intelligence (AI) and TPD technology. The company develops molecules that can specifically degrade proteins in diseased cells that pose a threat to health. These molecules are designed to recognize and bind to disease-causing proteins. Once the artificially created molecule binds to the protein, it is disposed of by the cell. The target diseases for C4 are cancer, as well as immune, nervous, and metabolic system diseases. The company has two business areas: Therapeutics and Platforms. In the Therapeutics area, C4 Therapeutics specifically develops drugs to treat cancer and various other diseases. The company already has a product in the clinical phase that is being used to treat patients with advanced stages of cancer. C4T-412 is a molecule designed to eliminate the protein FUBP1, which is overexpressed in many types of cancer and promotes tumor cell growth. In the Platforms area, C4 Therapeutics offers its customers custom services and products that utilize TPD technology. The company has a data platform that allows customers to systematically identify disease proteins. Using artificial intelligence, the precise structure of the disease-causing protein and the appropriate molecules capable of degrading the protein are identified. C4 Therapeutics also offers drug development tools that allow customers to develop their own TPD therapeutics. C4 Therapeutics has formed partnerships with industry leaders such as Roche, Calico, and Novartis. These partnerships facilitate knowledge transfer and often involve collaborative research and development. The company has also formed partnerships with contract research organizations, which allow C4 to expand its development and manufacturing capabilities. The company has a broad intellectual property base and has already received several patents related to its technology and products. C4 Therapeutics has raised over $200 million in venture capital to support the development of its TPD therapeutics and the expansion of its business. In summary, C4 Therapeutics pursues an innovative business model based on the combination of artificial intelligence and TPD technology. The company aims to provide tailored solutions for the treatment of various diseases and has already made progress in the development of TPD therapeutics. With its partnerships and broad intellectual property base, C4 Therapeutics is well positioned to continue growing and expanding in the future.

C4 Therapeutics membayarkan dividen sebesar 0 USD yang dibagi melalui pembayaran dalam setahun.

Dividen untuk C4 Therapeutics saat ini tidak dapat dihitung atau perusahaan tidak membagikan dividen.

ISIN dari C4 Therapeutics adalah US12529R1077.

Ticker dari C4 Therapeutics adalah CCCC.

Dalam 12 bulan terakhir, C4 Therapeutics membayar dividen sebesar . Ini setara dengan yield dividen sekitar . Untuk 12 bulan mendatang, C4 Therapeutics diperkirakan akan membayar dividen sebesar 0 USD.

Imbal hasil dividen dari C4 Therapeutics saat ini adalah .

C4 Therapeutics membayar dividen setiap kuartal. Dividen ini dibayarkan pada bulan .

C4 Therapeutics membayar dividen setiap tahun dalam 0 tahun terakhir.

Untuk 12 bulan ke depan, diperkirakan akan ada dividen sebesar 0 USD. Ini setara dengan yield dividen sebesar 0 %.

C4 Therapeutics dikelompokkan dalam sektor 'Kesehatan'.

Untuk menerima dividen terakhir dari C4 Therapeutics tanggal 24/8/2025 sejumlah 0 USD, Anda harus memiliki saham tersebut di portofolio sebelum tanggal Ex-Tag pada 24/8/2025.

Pembayaran dividen terakhir dilakukan pada 24/8/2025.

Pada tahun 2024, C4 Therapeutics 0 USD telah dibayarkan sebagai dividen.

Dividen dari C4 Therapeutics dibayarkan dalam USD.